Watch TNDM. Know when insiders buy.
One email the day a filing lands. Free.
TNDM
TANDEM DIABETES CARE INC
16.35
−0.17 −1.03%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
25
FLAG · shorts 25
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
1 / 0
buys / sells · latest disclosed Oct 12
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1.1BP/E —DIV YIELD —FCF YIELD -2.34%REV TTM $1B +4.0%NET INCOME −$63.3MNET DEBT $19.9M52W 12.82 – 28.26SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $254.6M | +5.8% | 56.9% | −$13.8M | −$21.2M | — | -0.31 | −$34.6M | $4M | −$38.7M | Aug 6 |
| Q1 2026 · Mar 31 | $247.2M | +5.5% | 55.3% | −$17.4M | −$20.4M | — | -0.30 | $11.1M | $6.3M | $4.8M | May 7 |
| Q4 2025 · Dec 31 | $290.4M | +2.7% | 57.7% | $8.3M | −$589K | −178.0% | -0.01 | $9.8M | $6.7M | $3.1M | Feb 19 |
| Q3 2025 · Sep 30 | $249.3M | +2.2% | 53.9% | −$22.9M | −$21.2M | — | -0.31 | $8.3M | $4.1M | $4.2M | Nov 6 |
| Q2 2025 · Jun 30 | $240.7M | +8.5% | 52.3% | −$51.8M | −$52.4M | — | -0.78 | −$9.5M | $6.2M | −$15.7M | Aug 6 |
| Q1 2025 · Mar 31 | $234.4M | +22.3% | 50.5% | −$120.9M | −$130.6M | — | -1.97 | −$18.3M | $3M | −$21.2M | May 7 |
| Q4 2024 · Dec 31 | $282.6M | +43.6% | 55.7% | −$581K | $755K | — | 0.01 | $10.7M | $3.1M | $7.6M | Feb 19 |
| Q3 2024 · Sep 30 | $244M | +31.4% | 51.1% | −$26.1M | −$23.3M | — | -0.35 | $26.8M | $5.2M | $21.5M | Nov 6 |
| Q2 2024 · Jun 30 | $221.9M | — | 50.8% | −$30.8M | −$30.8M | — | -0.47 | −$5.3M | $6.5M | −$11.7M | Aug 6 |
| Q1 2024 · Mar 31 | $191.7M | — | 49.4% | −$41.7M | −$42.7M | — | -0.65 | −$8M | $4.5M | −$12.5M | Apr 30 |
| Q4 2023 · Dec 31 | $196.8M | — | 47.4% | −$35.1M | −$30M | — | -0.46 | −$7.2M | $5.2M | −$12.4M | Feb 19 |
| Q3 2023 · Sep 30 | $185.6M | — | 48.4% | −$31.5M | −$33M | — | -0.51 | $55K | $5.4M | −$5.3M | Nov 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $1B | 53.8% | −$187.3M | −$204.7M | -20.2% | -3.04 | −$9.7M | $19.9M | −$29.7M | $0 | — |
| FY2024 · to Dec 31 | $940.2M | 52.1% | −$99.1M | −$96M | -10.2% | -1.47 | $24.2M | $19.2M | $5M | $30M | — |
| FY2023 · to Dec 31 | $747.7M | 49.2% | −$233.2M | −$222.6M | -29.8% | -3.43 | −$31.8M | $26.8M | −$58.6M | $0 | — |
| FY2022 · to Dec 31 | $801.2M | 51.5% | −$92.8M | −$94.6M | -11.8% | -1.47 | $50.5M | $34.1M | $16.4M | $0 | — |
| FY2021 · to Dec 31 | $702.8M | 53.5% | $22.7M | $15.6M | 2.2% | 0.24 | $111.4M | $14.2M | $97.2M | — | — |
| FY2020 · to Dec 31 | $498.8M | 52.2% | −$8M | −$34.4M | -6.9% | -0.56 | $24.7M | $27.4M | −$2.7M | — | — |
Every number comes from TANDEM DIABETES CARE INC's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.